Rapamycin (low-dose)
Longevity-focused mTOR modulation, closely provider-guided.
What it is
A longevity-focused, low-dose use of an established medication that modulates the mTOR pathway.
Who it’s for
Health-focused adults exploring evidence-guided longevity interventions, with close provider oversight.
How it works
Intermittent low dosing modulates mTOR, a key regulator of cellular aging, while minimizing side effects. Careful monitoring is required.
What to expect
A long-horizon intervention focused on healthspan, guided by regular labs and provider review.
Anyone can sell you the prescription. Almost nobody watches what it does.
The prescription is the cheap half. The expensive half is knowing whether it worked, catching what it moved, and changing it when the numbers say so.
We make our money on the membership. Not on your medication.
Membership
$38.50/mo
Clinician, record, unlimited messages, and every protocol change.
Or $360 for the year, with your 160+ biomarker panel included.
Medication
Cost plus a markup confirmed at launch
Compounded and shipped from a US-licensed pharmacy.
Panels
Confirmed at launch
Baseline before you start, then monitoring every quarter.
The basics, answered.
Is this covered by insurance?
Prime Years is cash-pay by design: no claims and no prior authorizations. You get transparent pricing and faster access.
How do I get started?
Complete the online intake. A licensed provider reviews your goals, history, and labs, then designs a protocol if you’re a fit.
How is my progress tracked?
Your biomarkers and symptoms are monitored over time in your PYM Analysis dashboard, so your protocol can be fine-tuned.
Find out whether you actually need this.
Bring a panel from any lab in the country and your Prime Score is read from it. Enrollment is not open yet, so this starts with the waitlist.
This page is illustrative and pre-launch. Rapamycin (low-dose) is described in general terms; eligibility, dosing and outcomes are determined by a licensed clinician based on your evaluation. Final product and medical copy pending clinical and legal review.